TrialJournal for immunotherapy of cancer2019

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.

Michael Fehlings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.